Grade My Investments
HomeFree Stock Grades › CDXS

Codexis, Inc. (CDXS) Stock Grade

CDXS · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$142.0M
P/E Ratio
Revenue Growth (YoY)
+18.6%
Net Margin
-62.5%
Return on Equity
Dividend Yield
None

About Codexis, Inc.'s fundamentals

Codexis is a biotechnology company with a market capitalization of $142.0 million that is experiencing revenue growth of 18.6% year-over-year, indicating expanding business activity. However, the company operates at a significant loss, with a net margin of -62.5%, meaning it spends substantially more than it generates in revenue. The company does not currently pay a dividend and reported a net loss in its latest annual statement, reflecting typical characteristics of early-stage biotech firms that prioritize research and development spending over profitability.

Track CDXS free — no credit card required. Live grade + monthly AI report →